December 11th 2023
Pierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.
April 10th 2023
Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
April 3rd 2023
Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.
In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.
March 27th 2023
In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.
Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.
March 20th 2023
Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.
Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.
March 13th 2023
Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.
A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.
March 6th 2023
Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.
Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.
February 20th 2023
Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.
Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.
Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.
Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).
August 24th 2022
Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.
August 17th 2022
Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.
Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
August 10th 2022
Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.